Overview

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis
Phase:
Phase 2
Details
Lead Sponsor:
C.T. Development America, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions